Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000925 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00000925 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 56 participants.
The verdict
NCT00000925, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a high-quality protein food supplement will help HIV-positive patients maintain, and possibly gain, muscle mass. Many HIV-positive patients lose weight that they are then unable to regain. This may be because patients are not eating enough protein or are not eating the right kinds of protein. The protein eaten in foods (such as meat, eggs, or beans) may not be able to make up for the amount of protein lost due to HIV infection. This study gives patients high-quality protein food supplements to help them maintain and/or gain weight.
Interventions
- DRUG Optimune oral nutritional supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 1999-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000925
The ClinicalTrials.gov registry entry for NCT00000925 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Optimune oral nutritional supplement is the first listed.
NCT00000925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000925 about?
NCT00000925 is a clinical study titled "A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss". The purpose of this study is to determine whether a high-quality protein food supplement will help HIV-positive patients maintain, and possibly gain, muscle mass. Many HIV-positive patients lose weight that they are then unable to regain. This may be because patients are not eating enough protein o...
What is the current status of trial NCT00000925?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 1999-05.
What interventions are being tested in trial NCT00000925?
The interventions under investigation include: Optimune oral nutritional supplement (DRUG).
Who is sponsoring clinical trial NCT00000925?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.